All In Biotech

Drug Trial Radar · NCT05473156

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

A Phase 1/2, Open-label Study of the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Jul 24, 2023

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
AP Biosciences Inc.Industry
Sponsor type
Industry
First posted
Jul 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and antitumor activities of AP203 in adult patients with locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced or Metastatic Solid Tumors
  • Non Small Cell Lung Cancer (NSCLC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

  • AP203Drug

    Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D\[s\]). Participants will be administered by intravenous (IV) infusion, every week (Q1W \[± 1days\]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W \[± 3 days\]) for all the following doses.

  • AP203Drug

    The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Escalation: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: The initial 28 days and completion of the first 4 doses of treatment
  2. Both Dose-Escalation and Dose-Expansion: Number of Participants With Adverse Events (AEs) and Serious AEsTime frame: At screening (≤ 28 days before the first dose of AP203), up to 90 days after the last dose
  3. Dose-Expansion: Overall response rate(ORR) (assessed by the Investigator according to RECIST version 1.1)Time frame: At screening (≤ 28 days before the first dose of AP203, up to 90 days after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • AP Biosciences Inc.

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.